| Size | Price | |
|---|---|---|
| 100mg | ||
| Other Sizes |
| Targets |
Oleic acid-13C18 itself does not have a traditional biological target; it is a stable isotope-labeled tracer. The parent compound Oleic acid is a Na+/K+ ATPase activator, influencing cellular ion homeostasis and energy metabolism. Oleic acid-13C18 is used to track fatty acid uptake, β-oxidation, and incorporation into complex lipids in metabolic studies.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Oleic acid-13C18 does not exhibit direct in vitro biological activity as it is an isotopically labeled tracer. However, the parent compound Oleic acid is a Na+/K+ ATPase activator. In cell culture studies, Oleic acid-13C18 is used to trace fatty acid metabolic pathways, including β-oxidation and triglyceride synthesis, by monitoring the incorporation of 13C into downstream metabolites using mass spectrometry. |
| ln Vivo |
Oleic acid-13C18 is not administered as a therapeutic agent; it is used as a metabolic tracer in in vivo studies. When administered to animal models, it allows researchers to track fatty acid metabolism, including absorption, distribution, oxidation, and incorporation into complex lipids. The labeled compound is used to study lipid metabolism in health and disease, including obesity, diabetes, and cardiovascular disease.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Oleic acid-13C18 are not applicable, as it is a metabolic tracer rather than a bioactive compound. Quality control assays involve HPLC or mass spectrometry to verify isotopic purity (≥99 atom % 13C) and chemical purity. The compound is also tested for solubility and stability under recommended storage conditions. It is soluble in organic solvents such as chloroform and methanol.
|
| Cell Assay |
In vitro cellular assays for Oleic acid-13C18 involve metabolic tracing studies rather than traditional bioactivity assays. Cells, such as HepG2 hepatoma cells, are cultured in media containing Oleic acid-13C18, and the incorporation of 13C into fatty acid metabolites and triglycerides is measured by LC-MS or GC-MS. These studies allow researchers to quantify fatty acid flux through β-oxidation, lipogenesis, and other pathways.
|
| Animal Protocol |
In vivo animal studies for Oleic acid-13C18 involve metabolic tracing experiments. Animals are administered the labeled fatty acid via oral or intravenous routes. Blood, tissues, and excreta are collected at various time points, and the 13C enrichment in fatty acid metabolites is measured by mass spectrometry. These studies provide insights into whole-body fatty acid metabolism, including lipid oxidation, storage, and turnover. They are used in metabolic disease and nutritional research.
|
| ADME/Pharmacokinetics |
Oleic acid-13C18 has a molecular formula of 13C18H34O2 and a molecular weight of 300.33. It appears as a solid or liquid with a purity of ≥98% and an isotopic enrichment of ≥99 atom % 13C. It is soluble in organic solvents. The compound is stable under recommended storage conditions. It is intended for research use only and is not for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Oleic acid-13C18 is not extensively characterized, as it is a stable isotope-labeled tracer rather than a therapeutic agent. The parent compound Oleic acid is a common dietary fatty acid that is generally recognized as safe. Standard safety data for handling isotopically labeled compounds in laboratory settings would apply. Oleic acid-13C18 is intended for research use only and is not approved for clinical use.
|
| References | |
| Additional Infomation |
Oleic acid-13C18 (CAS 287100-82-7) is a stable isotope-labeled form of oleic acid, in which all 18 carbon atoms are enriched with carbon-13. This monounsaturated fatty acid serves as a Na+/K+ ATPase activator. Oleic acid-13C18 was used to prepare stable isotope-labeled fatty acid (FA) mixtures and for the isotopic labeling of triglycerides in HepG2 hepatoma cells. It is intended for research use only and is not approved for clinical use.
|
| Molecular Formula |
13C18H34O2
|
|---|---|
| Molecular Weight |
300.329152584076
|
| Exact Mass |
300.316
|
| CAS # |
287100-82-7
|
| Related CAS # |
Oleic acid;112-80-1
|
| PubChem CID |
16213466
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.947 g/mL at 25 °C
|
| Boiling Point |
192-195 °C1.2 mm Hg(lit.)
|
| Melting Point |
13.4 °C(lit.)
|
| Flash Point |
>230 °F(lit.)
|
| Index of Refraction |
n20/D 1.4595(lit.)
|
| LogP |
6.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
20
|
| Complexity |
234
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[13CH2]([13CH2][13CH2][13CH2][13CH2][13CH2][13C](=O)O)[13CH2]/[13CH]=[13CH]\[13CH2][13CH2][13CH2][13CH2][13CH2][13CH2][13CH2][13CH3]
|
| InChi Key |
ZQPPMHVWECSIRJ-IGBBIXMTSA-N
|
| InChi Code |
InChI=1S/C18H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h9-10H,2-8,11-17H2,1H3,(H,19,20)/b10-9-/i1+1,2+1,3+1,4+1,5+1,6+1,7+1,8+1,9+1,10+1,11+1,12+1,13+1,14+1,15+1,16+1,17+1,18+1
|
| Chemical Name |
(Z)-(1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18-13C18)octadec-9-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3297 mL | 16.6484 mL | 33.2967 mL | |
| 5 mM | 0.6659 mL | 3.3297 mL | 6.6593 mL | |
| 10 mM | 0.3330 mL | 1.6648 mL | 3.3297 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
